Literature DB >> 7327369

Cytotoxic cells induced in tumor-bearing rats by a streptococcus preparation (OK-432).

H Hojo, Y Hashimoto.   

Abstract

The characteristics of the cytotoxic cells induced by ip injections of an immunoadjuvant, OK-432 (Picibanil), into ACI/N rats bearing syngeneic bladder cancer, BC47, were examined. The cytostatic activity, but not the cytolytic activity, of peritoneal macrophages was augmented when either normal or cancer-bearing rats were treated with OK-432. In contrast, the plastic nonadherent cells of the peritoneal exudate cells from OK-432-treated cancer bearing rats, but not lymph node cells or spleen cells, killed all ACI/N rat bladder cancers tested as well as ACI/N rat hepatoma cells and Meth-A mouse sarcoma cells. The plastic nonadherent cells from OK-432-treated normal rats also killed hepatoma cells and Meth-A cells, but not bladder cancer cells. The cytolytic cells that were induced in cancer-bearing rats by OK-432 treatment and showed cytolytic activity specific for bladder cancer were found to be sensitive to anti-rat thymocyte serum and complement, nylon-adherent, and Fc receptor-negative. The cells that showed nonselective cytolytic activity were nylon-adherent and insensitive to anti-rat thymocyte serum and complement.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7327369

Source DB:  PubMed          Journal:  Gan        ISSN: 0016-450X


  16 in total

1.  Pronounced antitumor effect of LAK-like cells induced in the peritoneal cavity of mice after intraperitoneal injection of OK-432, a killed streptococcal preparation.

Authors:  M Saito; O Ichimura; M Kataoka; Y Moriya; K Ueno; Y Sugawara; M Nanjo; N Ishida
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

2.  Postoperative adjuvant immunochemotherapy with mitomycin C, tegafur, PSK and/or OK-432 for gastric cancer, with special reference to the change in stimulation index after gastrectomy.

Authors:  T Hattori; T Nakajima; H Nakazato; T Tanabe; K Kikuchi; O Abe; T Kondo; T Taguchi; N Komi; K Sugimachi
Journal:  Jpn J Surg       Date:  1990-03

3.  Inhibition of in vitro LAK generation by OK-432.

Authors:  M Yagita; E A Grimm
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

4.  Induction of activated natural killer cells from murine spleen cells primed in vivo and subsequently challenged in vitro with the streptococcal preparation OK432.

Authors:  H Yamaue; M Katsumi; K Tabuse; Y Tabuse; K Kuribayashi; T Nishihara; K Saito
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

5.  Anti-tumor effect of intravesical instillation of OK432 against rat bladder tumors induced by N-butyl-N-(4-hydroxybutyl) nitrosamine.

Authors:  H Tsujihashi; H Matsuda; S Uejima; T Akiyama; T Kurita
Journal:  Urol Res       Date:  1990

6.  In vitro interferon producing activity of peripheral mononuclear cells in patients with chronic liver disease.

Authors:  K Matsushita; T Arima; H Nagashima
Journal:  Gastroenterol Jpn       Date:  1987-04

7.  Induction of antitumor L3T4-positive T cells by OK-432 at tumor sites in mice.

Authors:  Y Moriya; H Sato; K Ito; M Saito; T Yoshida; N Ishida
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

8.  The efficacy of the inhalation of an aerosolized Group A streptococcal preparation in the treatment of lung cancer.

Authors:  Jun Liu; Xiang Liu; Fei Cui; Guoqin Chen; Yubao Guan; Jianxing He
Journal:  Chin J Cancer Res       Date:  2012-12       Impact factor: 5.087

9.  Recruitment of T lymphocytes and induction of tumor necrosis factor in thyroid cancer by a local immunotherapy.

Authors:  T Misaki; Y Watanabe; Y Iida; A Hidaka; K Kasagi; H Fukushima; J Konishi
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

10.  Significant antitumor effect of a synthetic lipid A analogue, DT-5461, on murine syngeneic tumor models.

Authors:  E Kumazawa; A Tohgo; T Soga; T Kusama; Y Osada
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.